APUS (Apimeds Pharmaceuticals Us) EBIT: $-39.55 Mil (TTM As of Mar. 2026)

What is Apimeds Pharmaceuticals Us EBIT?

Apimeds Pharmaceuticals Us APUS -2.04% 14 EBIT is $-39.55 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Apimeds Pharmaceuticals Us's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-34.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Apimeds Pharmaceuticals Us's annualized ROC % for the quarter that ended in Mar. 2026 was -32.66%. Apimeds Pharmaceuticals Us's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,066.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Apimeds Pharmaceuticals Us's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -219.82%.

Apimeds Pharmaceuticals Us (AMEX:APUS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Apimeds Pharmaceuticals Us's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-48.744 * ( 1 - 0% )	/	( (159.447	+	139.062)	/ 2 )
=	-48.744	/	149.2545
=	-32.66 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	164.184	-	1.459	-	( 3.637	-	max(0, 10.706	-	13.984	+	3.637	))
=	159.447

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	141.219	-	3.589	-	( 2.48	-	max(0, 14.585	-	13.153	+	2.48	))
=	139.062

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Apimeds Pharmaceuticals Us's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-136.8	/	( ( (0.239 + max(7.272, 0))	+	(0.228 + max(5.503, 0)) )	/	2 )
=	-136.8	/	( ( 7.511	+	5.731 )	/	2 )
=	-136.8	/	6.621
=	-2,066.15 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	10.347)	-	(1.459	+	0	+	1.616)
=	7.272

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	10.673)	-	(3.589	+	0	+	1.581)
=	5.503

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Apimeds Pharmaceuticals Us's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-39.554	/	17.994
	=	-219.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us EBIT Related Terms

Apimeds Pharmaceuticals Us EBIT Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's EBIT can be seen below:

Apimeds Pharmaceuticals Us EBIT Chart

Apimeds Pharmaceuticals Us Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

-1.02

-0.64

-0.74

-1.27

-5.72

Apimeds Pharmaceuticals Us Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial										-0.36	-2.64	-1.78	-0.94	-34.20

APUS vs KAYS, BIOE, BFRI: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apimeds Pharmaceuticals Us EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Apimeds Pharmaceuticals Us's EV-to-EBIT falls into.

Save Embed

14GF Score

Apimeds Pharmaceuticals Us Inc APUS

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Apimeds Pharmaceuticals Us EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.55 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-39.55 Mil mean?

Apimeds Pharmaceuticals Us (APUS) has a EBIT of $-39.55 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Apimeds Pharmaceuticals Us.

Is Apimeds Pharmaceuticals Us' EBIT too high?

Apimeds Pharmaceuticals Us' current EBIT is $-39.55 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Apimeds Pharmaceuticals Us' EBIT compare to KAYS and BIOE?

Apimeds Pharmaceuticals Us' EBIT of $-39.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Apimeds Pharmaceuticals Us. Apimeds Pharmaceuticals Us's current EBIT is $-39.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Apimeds Pharmaceuticals Us stock overvalued right now?

Apimeds Pharmaceuticals Us (APUS) has a current EBIT of $-39.55 Mil. The current EBIT is $-39.55 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current EBIT is $-39.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies KAYS BIOE BFRI IGPK CABR SXTC AKAN YCBD GELS SNOA XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747

Website https://www.apimedsus.com

Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

14GF Score

Get the complete analysis for APUS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72

Price

View APUS Analysis

See EBIT data for all stocks →